Ardelyx (ARDX) Equity Average (2014 - 2026)
Ardelyx posted quarterly Equity Average of $157.8 million for Q1 2026, down 1.06% year-on-year from $159.5 million in Q1 2025, and down 1.76% on a QoQ basis from $160.6 million in Q4 2025.
Ardelyx (ARDX) has 13 years of Equity Average data on file, last reported at $157.8 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 1.06% year-over-year to $157.8 million; the trailing twelve-month figure through Mar 2026 stood at $157.8 million (down 1.06% YoY), and the FY2025 full-year result was $170.1 million, changed 0.04% from the prior year.
- Equity Average for Q1 2026 stood at $157.8 million, down from $160.6 million in the prior quarter.
- Across five years, Equity Average topped out at $179.0 million in Q4 2023 and bottomed at $58.6 million in Q2 2022.
- The 5-year median for Equity Average is $148.9 million (2024), against an average of $131.8 million.
- The widest annual swing landed in 2022, when Equity Average plunged 52.8%; it then surged 162.15% in 2023.
- A 5-year view of Equity Average shows it stood at $82.6 million in 2022, then soared by 116.71% to $179.0 million in 2023, then decreased by 7.37% to $165.8 million in 2024, then fell by 3.12% to $160.6 million in 2025, then dropped by 1.76% to $157.8 million in 2026.
- The last three Equity Average figures came in at $157.8 million (Q1 2026), $160.6 million (Q4 2025), and $146.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn | 157.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.79 Mn |
| Dec 31, 2025 | 160.61 Mn |
| Sep 30, 2025 | 146.91 Mn |
| Jun 30, 2025 | 142.60 Mn |
| Mar 31, 2025 | 159.48 Mn |
| Dec 31, 2024 | 165.79 Mn |
| Sep 30, 2024 | 152.64 Mn |
| Jun 30, 2024 | 148.94 Mn |
| Mar 31, 2024 | 158.85 Mn |
| Dec 31, 2023 | 178.99 Mn |
| Sep 30, 2023 | 157.16 Mn |
| Jun 30, 2023 | 124.29 Mn |
| Mar 31, 2023 | 111.88 Mn |
| Dec 31, 2022 | 82.60 Mn |
| Sep 30, 2022 | 59.95 Mn |
| Jun 30, 2022 | 58.62 Mn |
| Mar 31, 2022 | 73.40 Mn |
| Dec 31, 2021 | 82.02 Mn |
| Sep 30, 2021 | 99.50 Mn |
| Jun 30, 2021 | 124.19 Mn |
| Mar 31, 2021 | 128.46 Mn |
| Dec 31, 2020 | 128.73 Mn |
| Sep 30, 2020 | 138.85 Mn |
| Jun 30, 2020 | 157.05 Mn |
| Mar 31, 2020 | 177.21 Mn |
| Dec 31, 2019 | 117.91 Mn |
| Sep 30, 2019 | 58.89 Mn |
| Jun 30, 2019 | 80.23 Mn |
| Mar 31, 2019 | 103.83 Mn |
| Dec 31, 2018 | 128.63 Mn |
| Sep 30, 2018 | 152.43 Mn |
| Jun 30, 2018 | 146.19 Mn |
| Mar 31, 2018 | 134.14 Mn |
| Dec 31, 2017 | 132.97 Mn |
| Sep 30, 2017 | 135.81 Mn |
| Jun 30, 2017 | 156.33 Mn |
| Mar 31, 2017 | 180.42 Mn |
| Dec 31, 2016 | 208.02 Mn |
| Sep 30, 2016 | 181.75 Mn |
| Jun 30, 2016 | 154.18 Mn |
| Mar 31, 2016 | 138.32 Mn |
| Dec 31, 2015 | 117.02 Mn |
| Sep 30, 2015 | 133.70 Mn |
| Jun 30, 2015 | 100.13 Mn |
| Mar 31, 2015 | 59.34 Mn |
| Dec 31, 2014 | 61.99 Mn |
| Sep 30, 2014 | 63.08 Mn |